Pluristem Therapeutics (PSTI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
2,128 shs
Average Volume
715,259 shs
Market Capitalization
$32.35 million
P/E Ratio
Dividend Yield
Price Target
PSTI stock logo

About Pluristem Therapeutics Stock (NASDAQ:PSTI)

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

PSTI Stock News Headlines

NBRVF Nabriva Therapeutics plc
Pluri CEO Issues Shareholder Update
Pluristem: Fiscal Q3 Earnings Snapshot
See More Headlines
Receive PSTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological Products, Except Diagnostic
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.80 per share


Free Float
Market Cap
$32.35 million

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Yaacov Yanay (Age 51)
    Pres, CEO & Director
    Comp: $612.6k
  • Ms. Chen Franco-Yehuda (Age 38)
    CFO, Treasurer & Sec.
    Comp: $330.3k
  • Mr. Lior Raviv
    Chief Technology Officer
  • Ms. Efrat Livne-Hadass
    VP of HR
  • Dr. Nitsan Halevy M.D.
    Chief Medical Officer
  • Mr. Nimrod Bar Zvi
    Chief Commercial Officer

PSTI Stock Analysis - Frequently Asked Questions

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05.

When did Pluristem Therapeutics' stock split?

Pluristem Therapeutics shares reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

This page (NASDAQ:PSTI) was last updated on 5/20/2024 by Staff

From Our Partners